Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Paclitaxel Stories

2013-10-22 08:34:13

BUFFALO, N.Y., Oct. 22, 2013 /PRNewswire/ -- Kinex Pharmaceuticals and Hanmi Pharmaceutical Co., Ltd. are pleased to announce the execution of an agreement for Kinex Pharmaceuticals to lead the development of the Orascovery program in Malaysia, Thailand, Vietnam, the Philippines, and Indonesia. The addition of these five new countries is part of the strategic plan to support Kinex and Hanmi's joint effort to execute a regulatory strategy in Asia. This also strengthens the existing...

2013-10-17 16:30:52

NEJM today publishes findings of international trial resulting in recent FDA approval of Abraxane (nab-paclitaxel) for patients with advanced pancreatic cancer By all measures, the addition of nab-paclitaxel for the treatment of patients with advanced pancreatic cancer was superior to the survival for patients who received only gemcitabine, according to the results of a study led by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, published today by The New...

2013-10-16 16:25:36

MIAMI, Oct. 16, 2013 /PRNewswire-USNewswire/ -- In a study to be published today in Scientific Reports, researchers from the Florida International University Herbert Wertheim College of Medicine and the FIU College of Engineering and Computing describe what could be a breakthrough in the treatment of ovarian cancer: a novel way to deliver cancer-killing drugs using nanotechnology. In their lab experiments, Taxol, a chemotherapy drug used to treat ovarian cancer, was loaded unto a...

2013-10-15 08:33:04

BUFFALO, N.Y., Oct. 15, 2013 /PRNewswire/ -- Kinex Pharmaceuticals, a leading specialty biotech focused on the development and commercialization of next generation oral therapies for cancer and immunomodulatory diseases is pleased to welcome Dr. Daniel Von Hoff, MD, F.A.C.P., as Chair of its Clinical Advisory Committee. Dr. Von Hoff is highly regarded as a medical oncologist and drug developer by his colleagues worldwide. As the current Physician-in-Chief at the Translational...

2013-10-09 20:22:35

MAJESTIC Trial To Study Self-Expanding DES System Designed To Treat Superficial Femoral Artery (SFA) Lesions NATICK, Mass., Oct. 9, 2013 /PRNewswire/ -- Launching a key clinical trial expected to serve as the foundation for global regulatory approvals, a physician in Auckland, New Zealand has performed the first patient implant of the Boston Scientific Corporation (NYSE: BSX) Innova(TM) Drug-Eluting Stent (DES) System. The MAJESTIC trial -- designed to evaluate the safety and...

2013-10-01 12:31:18

CALGARY, Oct. 1, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that abstracts detailing results from two Phase II studies examining the use of REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors (REO 016) and in patients with squamous cell carcinoma of the lung (REO 021), are now available on the International Association for the Study...

2013-09-24 23:40:13

Barnes-Jewish Hospital is the only hospital in the region implanting a new drug-eluting stent to treat symptomatic blockages of leg arteries caused by peripheral artery disease. St. Louis (PRWEB) September 24, 2013 Although drug-coated stents have been commonly used in coronary procedures, the technology is new to the treatment of peripheral artery disease (PAD). Patrick Geraghty, MD, FACS, Washington University vascular surgeon at Barnes-Jewish Hospital, is the first in the regional area...

Additive Found In Dog Food May Prevent A Disabling Chemotherapy Side Effect
2013-09-20 08:47:59

April Flowers for redOrbit.com - Your Universe Online A chemical commonly used as a dog food preservative might prevent the kind of painful nerve damage found in the hands and feet of four out of five cancer patients taking the chemotherapy drug Taxol. A team of Johns Hopkins researchers have been working with cells in test tubes and mice to investigate the Food and Drug Administration (FDA)-approved dog food preservative. The preservative, an antioxidant called ethoxyquin, has been...

2013-09-16 08:28:33

SAN DIEGO, Sept. 16, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today it will present the clinical data for Cynviloq(TM) (IG-001), which resulted in its approval as 1(st) line treatment of ovarian cancer by Korean FDA in March of 2013. Highlights of the findings include proof of non-inferiority of Cynviloq vs. Taxol in combination therapy with Carboplatin in patients with advanced epithelial ovarian cancer. These data will be presented at the...

2013-09-12 08:32:21

SAN DIEGO, Sept. 12, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with gemcitabine for the treatment of patients with stage IV metastatic pancreatic cancer will be presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) in Amsterdam. Additional data, including progression free and overall survival by hyaluronan (HA) status, will be...